European Stop Tyrosine Kinase Inhibitor Study (EURO-SKI)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01596114 |
Recruitment Status :
Completed
First Posted : May 10, 2012
Last Update Posted : November 5, 2021
|
Sponsor:
European LeukemiaNet
Information provided by (Responsible Party):
European LeukemiaNet
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date ICMJE | May 8, 2012 | |||
First Posted Date ICMJE | May 10, 2012 | |||
Last Update Posted Date | November 5, 2021 | |||
Actual Study Start Date ICMJE | May 30, 2012 | |||
Actual Primary Completion Date | December 3, 2014 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures ICMJE |
molecular relapse-free survival [ Time Frame: 3 years ] Evaluation of molecular relapse-free survival after stopping TKI (survival without molecular relapse defined by BCR-ABL1 > 0.1% on the IS at one time point (loss of major molecular response, MMR))
|
|||
Original Primary Outcome Measures ICMJE | Same as current | |||
Change History | ||||
Current Secondary Outcome Measures ICMJE |
|
|||
Original Secondary Outcome Measures ICMJE | Same as current | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title ICMJE | European Stop Tyrosine Kinase Inhibitor Study | |||
Official Title ICMJE | Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukemia After Stopping TKI | |||
Brief Summary | The EURO-SKI is a multicenter open label, uncontrolled trial estimating the persistence of molecular remission in Chronic Myeloid Leukemia (CML) patients after stopping Tyrosine Kinase Inhibitor (TKI). Main goal is the assessment of the duration of major molecular response (MMR) or better after stopping TKI therapy. Secondary goals include:
|
|||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
|||
Condition ICMJE | Chronic Myeloid Leukemia | |||
Intervention ICMJE | Other: Stopping treatment with TKI
stopping until loss of MMR
|
|||
Study Arms ICMJE | Experimental: Stop treatment
TKI treatment will be stopped in CML patients with very deep molecular responses for at least one year and at least 3 years TKI treatment
Intervention: Other: Stopping treatment with TKI
|
|||
Publications * |
|
|||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE |
868 | |||
Original Estimated Enrollment ICMJE |
500 | |||
Actual Study Completion Date ICMJE | December 31, 2019 | |||
Actual Primary Completion Date | December 3, 2014 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
|||
Sex/Gender ICMJE |
|
|||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Czechia, Denmark, Finland, France, Germany, Greece, Netherlands, Norway, Portugal, Sweden | |||
Removed Location Countries | Czech Republic | |||
Administrative Information | ||||
NCT Number ICMJE | NCT01596114 | |||
Other Study ID Numbers ICMJE | ELN-001 2011-000440-22 ( EudraCT Number ) |
|||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Current Responsible Party | European LeukemiaNet | |||
Original Responsible Party | Same as current | |||
Current Study Sponsor ICMJE | European LeukemiaNet | |||
Original Study Sponsor ICMJE | Same as current | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
|
|||
PRS Account | European LeukemiaNet | |||
Verification Date | October 2021 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |